Integrated genomic characterization of oesophageal carcinoma.
about
Recent advances in preoperative management of esophageal adenocarcinomaGenomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective.Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologistsGenomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterationsTherapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data.Epidemiology of Esophageal Squamous Cell Carcinoma.Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas.Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundariesMolecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer.Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients.UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients.Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.Single disease entity for both chromosomal instable subtype gastric adenocarcinoma and esophageal adenocarcinoma.Somatic mutations in ZFHX4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients.Computational Methods for Characterizing Cancer Mutational Heterogeneity.CDKN2A methylation in esophageal cancer: a meta-analysisWhole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma.A three-gene signature from protein-protein interaction network of LOXL2- and actin-related proteins for esophageal squamous cell carcinoma prognosis.The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring.Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer.Molecular subtypes in cancers of the gastrointestinal tract.Long Noncoding RNAs in the Pathogenesis of Barrett's Esophagus and Esophageal Carcinoma.EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?International cancer seminars: a focus on esophageal squamous cell carcinoma.Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing.Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution.Editorial on role of p53 in esophageal cancer from a meta-analysis of 16 studies by Fisher et al.Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre.Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma.Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus.Cancer genomics: Spot the difference.Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer.Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations.Deletion and downregulation of MTAP contribute to the motility of esophageal squamous carcinoma cells.Should cT2 esophageal cancer get neoadjuvant treatment before surgery?
P2860
Q33589301-515EAA68-E284-4703-BCA6-9195A39527FFQ33600507-197182C6-5E0D-4D55-81D8-6790D9B451A3Q33798665-B54A2BBE-12E4-4DFF-AD60-4BF1D06FF7F0Q33815746-3112053A-0AD2-41DE-BF5F-E60F2046A336Q33908553-670EC9B5-7DF8-475C-9317-9A13A4A49E77Q36320404-BBEFC119-8E36-4334-B05F-98680209270CQ38368693-D71AB80C-2689-4D85-BF61-9FAF906D6E92Q38599134-9FBCD538-B8F6-4F28-92B6-7FF1F8839667Q38613413-457E4294-5DA4-47B4-9C63-28B092E6B572Q38634656-AE885D5C-12B1-49E5-9314-AC708E04B563Q38637648-A2AA4BA8-9ECA-4BFB-80DA-31D630322F6EQ38647893-3B8382E8-0990-4750-B6FD-D63C9C87A014Q38649673-934DCF29-69BD-40C9-9B68-F02733078750Q38667837-04EAE34D-76C0-4D42-8201-63CFB8C4FBCDQ38669772-294F1D04-1618-4D83-9546-BB159FA3F194Q38677496-6C10AA37-5549-42C9-9657-FE45D5803B08Q38683298-DE81C991-BEAA-4ACB-BD3E-3D5995865BABQ38685341-0602F1BA-9890-422D-B3BD-E0944AB7095DQ38703541-433C4C9C-C7FA-46E0-82E7-F45974510FA9Q38715453-5A21E949-9EDC-4E05-9442-350FE030165DQ38728073-185EA025-026F-4394-8B80-7460B0552FA5Q38757261-254EA234-4910-446F-8F29-80E88CF8A14CQ39183864-16C7302A-76F5-44C3-9970-62D29A4EAA2FQ39204464-5D85F5CC-12CE-44E8-9E74-1D4FB445E0DEQ39235977-F1DB0599-653B-4C2F-B779-475D5F58DABEQ39320641-B4298662-2F01-432A-858C-7B819473EF88Q39340502-270F3E23-C046-48FC-B12A-99EEF34165F2Q40040780-1576831C-1DFC-4A6D-B5E6-BCAB38177DEEQ41198823-0459CD4C-07FC-4262-A9E0-1DE08F06B310Q41612476-476F3D20-DD21-4E89-872C-D48CBF68C050Q42131289-C0659099-3F48-45ED-A238-E4745D6B6794Q42332720-576D5BBE-D3D8-4264-BDDD-846E799AD71CQ42361543-5472A14F-17D0-43BA-B7DB-9E3175CD0C90Q42379227-7614E991-2FD7-4CDE-870F-B9BADA3912CFQ43728022-8BC6934E-6112-412A-8268-61AA1045AB58Q46126279-96ACC468-7999-4872-A9CD-85320FBFDCDBQ46430505-CD3E9D30-B8F5-41AD-AC83-F20EE04721EDQ46702063-E339E94B-EB06-40AB-95CA-A73F9E907373Q47097910-915E0AFC-11BA-4C3C-82C6-07F1A43E4262Q47104841-FE618E58-28B0-4B8C-B6F7-3DE6A0DCB40D
P2860
Integrated genomic characterization of oesophageal carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Integrated genomic characterization of oesophageal carcinoma.
@en
Integrated genomic characterization of oesophageal carcinoma.
@nl
type
label
Integrated genomic characterization of oesophageal carcinoma.
@en
Integrated genomic characterization of oesophageal carcinoma.
@nl
prefLabel
Integrated genomic characterization of oesophageal carcinoma.
@en
Integrated genomic characterization of oesophageal carcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Integrated genomic characterization of oesophageal carcinoma.
@en
P2093
Analysis Working Group: Asan University
Asan Medical Center
Asterand Bioscience
BC Cancer Agency
Barretos Cancer Hospital
BioreclamationIVT
Biospecimen Core Resource: International Genomics Consortium
Botkin Municipal Clinic
Broad Institute
Brown University
P2860
P2888
P304
P356
10.1038/NATURE20805
P407
P50
P577
2017-01-04T00:00:00Z
P6179
1045212192